Department of Structural Heart Disease, National Center for Cardiovascular Disease.
Fuwai Hospital, Chinese Academy of Medical Sciences.
Circ J. 2024 Aug 23;88(9):1383-1390. doi: 10.1253/circj.CJ-23-0800. Epub 2024 May 9.
Congenital left circumflex coronary artery fistula (LCX-CAF) is a relatively rare type of coronary artery fistula (CAF); little is known about the outcomes of transcatheter closure (TCC) of LCX-CAF.
All consecutive patients admitted to Fuwai Hospital and scheduled for TCC of LCX-CAF between January 2012 and December 2022 were reviewed retrospectively. Of the 25 consecutive patients (mean [±SD] age 34±20 years; 48% male) admitted and scheduled for TCC of congenital LCX-CAF, the procedure was feasible in 22 (77.3%). The mean (±SD) diameter of the fistulas was 6.99±2.04 mm; 21 (84%) patients had a large fistula (i.e., diameter >2-fold greater than non-feeding coronary artery). Occluders were deployed via a transarterial approach and arteriovenous loop in 6 (27.3%) and 16 (72.7%) patients, respectively. No procedural complications were recorded. Although the procedural success rates are similar for single LCX-CAF and left anterior descending CAF (81.25% vs. 92.86%; P=0.602), the mean time from initial angiography to first occluder deployment is significantly longer for LCX-CAF (83.06±36.07 vs. 36.00±9.49 min; P<0.001). The mean (±SD) follow-up time was 62.2±45.5 months. The incidence of myocardial infarction and recanalization of the fistula was 4.5% (1/22) and 9.1% (2/22), respectively.
TCC of LCX-CAF is a feasible and effective alternative to surgical repair, with comparable outcomes in selected patients. Optimal medical therapy to prevent post-closure myocardial infarction requires further investigation.
先天性左旋支冠状动脉瘘(LCX-CAF)是一种相对罕见的冠状动脉瘘(CAF)类型;对于 LCX-CAF 的经导管封堵(TCC)的结果知之甚少。
回顾性分析 2012 年 1 月至 2022 年 12 月期间连续收治并计划行 LCX-CAF TCC 的 25 例连续患者。在连续收治并计划行先天性 LCX-CAF TCC 的 25 例患者(平均年龄 34±20 岁;48%为男性)中,22 例(77.3%)可行 TCC。瘘管的平均(±SD)直径为 6.99±2.04mm;21 例(84%)患者存在大瘘管(即直径大于非供血冠状动脉的 2 倍)。分别通过经动脉途径和动静脉环在 6(27.3%)和 16(72.7%)例患者中部署封堵器。未记录到任何手术并发症。尽管单支 LCX-CAF 和左前降支 CAF 的手术成功率相似(81.25%与 92.86%;P=0.602),但 LCX-CAF 从初始血管造影到首次封堵器部署的时间明显更长(83.06±36.07 与 36.00±9.49min;P<0.001)。平均(±SD)随访时间为 62.2±45.5 个月。心肌梗死和瘘管再通的发生率分别为 4.5%(1/22)和 9.1%(2/22)。
LCX-CAF 的 TCC 是一种可行且有效的手术修复替代方法,在选择的患者中具有可比的结果。进一步需要研究优化预防封堵后心肌梗死的药物治疗。